Sophia Frentzas
Dr Sophia Frentzas, MBBS, BSc (Hons1), PhD, FRACP. is a Medical Oncologist and Adjunct Senior Lecturer at Monash University, leading the Early Phase Clinical Trials Unit at the Monash Health Translational Precinct. She has a distinguished background in translational and clinical research, having undertaken both specialty training and fellowships at the Drug Development Unit and Institute of Cancer Research (ICR) of the Royal Marsden Hospital, London.
Dr Frentzas is extensively published, with work focused on mechanisms of resistance to anti-angiogenic therapy in colorectal cancer and novel strategies for the management of solid tumours, especially those where immune-oncology and biomarkers are central. She has introduced more than 50 national and international clinical trials to Monash Health’s CTC and is the Monash Health Principal Investigator for over 20 ongoing phase I–III studies.
Her influence spans several steering groups, including the Victorian Comprehensive Cancer Centre and Monash Partners Comprehensive Cancer Consortium, with active memberships in ESMO, ASCO, AACR, MOGA, AGITG, and ANZGOG. She also sits on the board of directors for Cancer Trials Australia (CTA). Dr Frentzas’s reputation is built on her ability to bridge laboratory discovery and clinical application, bringing state-of-the-art cancer therapeutics to the patient bedside.
Research areas:
- Solid Organ Tumours
- Phase 1 trials
- Gynaecological Cancers
Professional Associations:
- Medical Oncology Group of Australia (MOGA)
- European Society For Medical Oncology (ESMO)
- American Society of Clinical Oncology (ASCO)
- Australian Gastrointestinal Trials Group (AGITG)
- Australia New Zealand Gynaecological Oncology Group (ANZGOG)